Compare Cytokinetics Inc (CYTK) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Quantum Computing Inc — how do they compare? Cytokinetics Inc trades at $82.61 (market cap $11.12B), while Quantum Computing Inc trades at $8.08 (market cap $1.88B). The key difference: Cytokinetics Inc is far larger — about 5.9× Quantum Computing Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | QUBT | |
|---|---|---|
Market Cap | $11.12B | $1.88B |
Sector | Technology | Technology |
52-Week High | $87.26 | $24.62 |
52-Week Low | $33.23 | $6.31 |
Enterprise Value | $11.59B | $894.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Quantum Computing Inc. (QUBT) trades at $8.00, down 7.62% amid sector-wide selling pressure. The stock shows bearish technical signals with negative moving averages but oversold RSI readings. Fundamentally, the company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, though it maintains strong analyst support with a $24.00 consensus price target representing 200% upside potential. Recent strategic acquisitions and commercial agreements highlight growth initiatives.
QUBT presents high-risk, high-reward potential with significant cash burn offset by promising technology positioning. The company's photonics-based quantum approach and government policy support provide growth catalysts, but profitability remains distant with negative margins. Investors face substantial execution risk amid competitive quantum computing landscape, though analyst consensus remains strongly bullish on long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
